They concluded that the increase of Tim‐3 in T cells may serve as a marker for the prognostic clinical response of Nivolumab treatment in patients with advanced ESCC.22 Koyama et al 68previously proved that the failure in PD‐1 blockade was related to the upregulation of Tim‐3. The gene discussed is HAVCR2; the disease is esophageal squamous cell carcinoma.